# ALTO-100 in MDD and/or PTSD

> **NCT05117632** · PHASE2 · COMPLETED · sponsor: **Alto Neuroscience** · enrollment: 245 (actual)

## Conditions studied

- Major Depressive Disorder
- Post Traumatic Stress Disorder

## Interventions

- **DRUG:** ALTO-100 PO tablet

## Key facts

- **NCT ID:** NCT05117632
- **Lead sponsor:** Alto Neuroscience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-20
- **Primary completion:** 2022-12-01
- **Final completion:** 2022-12-09
- **Target enrollment:** 245 (ACTUAL)
- **Last updated:** 2023-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05117632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05117632, "ALTO-100 in MDD and/or PTSD". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05117632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*